Dronabinol Interactions With Cognitive Enhancing Drug in Humans
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00842985|
Recruitment Status : Completed
First Posted : February 12, 2009
Results First Posted : December 17, 2012
Last Update Posted : May 30, 2017
Marijuana use is a major problem among veterans and non-veterans. A patient's use of marijuana while engaged in psychotherapy treatment may affect their memory and, therefore, limit their ability to benefit from treatment. This study is designed to test a new pharmacotherapy, modafinil, which has the potential to improve memory functioning in marijuana using individuals.
We hypothesize that modafinil treatment will decrease ratings of drug liking and improve cognitive measures, especially episodic memory.
|Condition or disease||Intervention/treatment||Phase|
|Cannabis Marijuana Abuse||Drug: drug condition||Early Phase 1|
The impairment of episodic memory in marijuana abusers has important treatment implications. Since many treatments, including cognitive-behavioral therapy, strongly utilize episodic memory, marijuana use during treatment may lead to diminished treatment outcomes. In addition, lessened response inhibition may lead to elevated rates of drug relapse while in treatment. Consequently, a treatment which will improve episodic memory and response inhibition may lead to improved treatment outcomes in marijuana users. One such treatment is modafinil.This study will be a 4 session within-subjects, double-blind, crossover study evaluating the impact of modafinil (400 mg/day) on the cognitive, subjective, and physiological effects of marijuana. Across 4 sessions, subjects will be randomly assigned to receive either oral placebo, modafinil (400mg), dronabinol (15mg), or dronabinol and modafinil. Outcome measures will include physiological, cognitive, and subjective drug effects.
Currently this study complete and has been published.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||53 participants|
|Intervention Model:||Sequential Assignment|
|Masking:||None (Open Label)|
|Official Title:||Dronabinol Interactions in Humans|
|Study Start Date :||September 2008|
|Actual Primary Completion Date :||October 2009|
|Actual Study Completion Date :||October 2009|
Participants received each drug condition in sequential order across 4 test days. Not all participants received the interventions in the same order.
Drug: drug condition
Dronabinol (15mg) or Modafinil (400mg) or Dronabinol + Modafanil or placebo
Other Name: Marinol, Provigil,
- CANTAB:CAmbridge Neuropsychological Test Automated Battery RVIP: Rapid Visual Information Processing [ Time Frame: Once for each test session (4 total). ]
CANTAB RVIP is one component of this computerized battery and is a measure of sustained attention with a working memory component.
This study used two subscales of the RVIP.
- RVP A' ( Target sensitivity, a measure of the ability to detect sequences.) The range is from 0-1; bad to good.
- RVP B'' ( Response bias, which is a measure of the tendency to respond regardless of whether a target is present.
The range is from -1 to +1 ; bad to good
The numbers represent probabilities as units on a scale.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00842985
|United States, Connecticut|
|Department of Veterans Affairs Hospital|
|West Haven, Connecticut, United States, 06516|
|Principal Investigator:||Mehmet Sofuoglu, M.D,Ph.D.||Yale University|